Dr Reddys Laboratories (RDY) Short-Term Debt issuances (2009)
Dr Reddys Laboratories (RDY) posted quarterly Short-Term Debt issuances of -$13.0 million for Q4 2009, up 7.14% quarter-over-quarter from -$14.0 million in Q3 2009.
Dr Reddys Laboratories (RDY) Short-Term Debt issuances (2009) Analysis & Trends
Dr Reddys Laboratories' Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at -$13.0 million for Q4 2009.
- In Q4 2009, Short-Term Debt issuances changed N/A year-over-year to -$13.0 million; the TTM figure through Dec 2009 stood at -$129.1 million (changed N/A YoY), while the FY2026 annual figure was $215.0 million, down 25.09% from the prior year.
- Short-Term Debt issuances for Q4 2009 stood at -$13.0 million, up from -$14.0 million in the prior quarter.
- The five-year high for Short-Term Debt issuances was -$13.0 million in Q4 2009, with the low at -$63.0 million in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 50.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | -13.00 Mn |
| Dec 31, 2009 | -13.00 Mn |
| Sep 30, 2009 | -14.00 Mn |
| Sep 30, 2009 | -14.00 Mn |
| Jun 30, 2009 | -63.00 Mn |
| Jun 30, 2009 | -63.00 Mn |